| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KPRXKiora Pharmaceuticals, Inc. | 8.05M | 2.19 | 2.52 | 22.47% | -38.12% | 100% | 0.00 | |
| KALAKALA BIO, Inc. | 16.74M | 0.60 | -0.09 | -141.11% | -388.29% | 2.62 | ||
| CLSDClearside Biomedical, Inc. | 5.81M | 1.11 | -0.16 | -79.77% | -7.81% | |||
| OTLKOutlook Therapeutics, Inc. | 33.47M | 0.52 | -0.29 | -25.93% | ||||
| ADVMAdverum Biotechnologies, Inc. | 96.26M | 4.36 | -0.66 | -72.22% | -130.93% | -189.84% | 1.30 | |
| IRDOpus Genetics, Inc. | 143.45M | 2.08 | -0.97 | -42.3% | -466.09% | -11.43% | ||
| SKYESkye Bioscience, Inc. | 30.87M | 0.96 | -1.32 | -156.01% | 0.01 | |||
| ALDXAldeyra Therapeutics, Inc. | 265.32M | 4.41 | -4.69 | -87.71% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 669.26K | 407.52K | 1.65M | 2.69M | 12.06K | 0 | 0 | 0 | 16M |
| Revenue Growth % | - | - | -0.39% | 3.06% | 0.63% | -1% | -1% | - | - | - |
| Cost of Goods Sold | 1.26K | 8.42M | 10.33M | 8.06M | 4.89K | 3.27M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 12.58% | 25.35% | 4.87% | 0% | 271.39% | - | - | - | - |
| Gross Profit | -1.26K | -7.75M | -9.92M | -6.4M | 2.68M | -3.26M | 0 | 0 | 0 | 16M |
| Gross Margin % | - | -11.58% | -24.35% | -3.87% | 1% | -270.39% | - | - | - | 1% |
| Gross Profit Growth % | - | -6167.09% | -0.28% | 0.35% | 1.42% | -2.22% | 1% | - | - | - |
| Operating Expenses | 6.68M | 14.02M | 14.97M | 12.5M | 9.8M | 3.61M | 14.24M | 12.31M | 12.59M | 11.49M |
| OpEx % of Revenue | - | 20.94% | 36.73% | 7.56% | 3.65% | 299.22% | - | - | - | 0.72% |
| Selling, General & Admin | 3.96M | 5.59M | 4.64M | 4.44M | 4.41M | 4.24M | 5.32M | 8.28M | 4.66M | 5.54M |
| SG&A % of Revenue | - | 8.36% | 11.38% | 2.69% | 1.64% | 352% | - | - | - | 0.35% |
| Research & Development | 2.72M | 8.42M | 10.33M | 8.06M | 5.39M | 3.57M | 5.35M | 3.45M | 4.03M | 4.9M |
| R&D % of Revenue | - | 12.58% | 25.35% | 4.87% | 2.01% | 295.72% | - | - | - | 0.31% |
| Other Operating Expenses | 0 | 0 | 4.64M | 0 | 0 | -4.2M | 3.56M | 582.61K | 3.9M | 1.05M |
| Operating Income | -6.68M | -13.35M | -14.56M | -10.84M | -7M | -6.87M | -14.24M | -12.31M | -12.59M | 4.51M |
| Operating Margin % | - | -19.94% | -35.73% | -6.56% | -2.61% | -569.61% | - | - | - | 0.28% |
| Operating Income Growth % | -1.71% | -1% | -0.09% | 0.26% | 0.35% | 0.02% | -1.07% | 0.14% | -0.02% | 1.36% |
| EBITDA | -6.68M | -13.34M | -14.54M | -10.81M | -6.79M | -6.84M | -14.19M | -12.27M | -12.54M | 4.53M |
| EBITDA Margin % | - | -19.93% | -35.68% | -6.54% | -2.53% | -566.84% | - | - | - | 0.28% |
| EBITDA Growth % | -1.71% | -1% | -0.09% | 0.26% | 0.37% | -0.01% | -1.08% | 0.14% | -0.02% | 1.36% |
| D&A (Non-Cash Add-back) | 1.26K | 5.18K | 19.29K | 38.48K | 213.93K | 33.4K | 45.3K | 41.61K | 51.8K | 19.2K |
| EBIT | -6.68M | -13.34M | -14.56M | -10.72M | -7M | -7.51M | -13.96M | -13.69M | -12.41M | 5.68M |
| Net Interest Income | -1.93M | 3.41K | -651 | 119.32K | 107.74K | 19.15K | -5.71K | 48.29K | 162.86K | 1.23M |
| Interest Income | 947 | 3.68K | 564 | 120.36K | 108.07K | 23.34K | 1.14K | 56.89K | 173.99K | 1.25M |
| Interest Expense | 1.93M | 275 | 1.22K | 1.04K | 325 | 4.19K | 6.85K | 8.6K | 11.13K | 21.45K |
| Other Income/Expense | 1.01M | 3.41K | -91.7K | 119.32K | 107.74K | 19.15K | 272.48K | -1.39M | 163.32K | 1.15M |
| Pretax Income | -8.39M | -13.34M | -14.56M | -10.73M | -7M | -6.85M | -13.96M | -13.7M | -12.42M | 5.66M |
| Pretax Margin % | - | -19.94% | -35.73% | -6.49% | -2.61% | -568.02% | - | - | - | 0.35% |
| Income Tax | 1.94M | 3.68K | -1.34M | 86.05K | 95.4K | 12.05K | -192.6K | -113.01K | 90.32K | 2.07M |
| Effective Tax Rate % | 1% | 1% | 0.91% | 1.01% | 1.01% | 1% | 0.99% | 0.99% | 1.01% | 0.64% |
| Net Income | -8.39M | -13.34M | -13.22M | -10.81M | -7.1M | -6.86M | -13.77M | -13.58M | -12.51M | 3.59M |
| Net Margin % | - | -19.94% | -32.44% | -6.54% | -2.64% | -569.02% | - | - | - | 0.22% |
| Net Income Growth % | -3.73% | -0.59% | 0.01% | 0.18% | 0.34% | 0.03% | -1.01% | 0.01% | 0.08% | 1.29% |
| Net Income (Continuing) | -8.39M | -13.34M | -13.22M | -10.81M | -7.1M | -6.86M | -13.77M | -13.58M | -12.51M | 3.59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -817.01 | -906.30 | -556.17 | -182.81 | -89.24 | -70.50 | -68.00 | -18.55 | -24.25 | 0.87 |
| EPS Growth % | -4.33% | -0.11% | 0.39% | 0.67% | 0.51% | 0.21% | 0.04% | 0.73% | -0.31% | 1.04% |
| EPS (Basic) | -817.01 | -906.30 | -556.17 | -182.81 | -89.24 | -70.50 | -68.00 | -18.55 | -24.25 | 0.93 |
| Diluted Shares Outstanding | 10.27K | 14.72K | 23.77K | 59.14K | 79.53K | 114.79K | 241.1K | 732.3K | 538.01K | 4.13M |
| Basic Shares Outstanding | 10.27K | 14.72K | 23.77K | 59.14K | 79.53K | 114.79K | 241.1K | 732.3K | 538.01K | 3.87M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.45M | 4.15M | 8.46M | 8.48M | 4.32M | 1.73M | 8.99M | 7.68M | 4.74M | 29.71M |
| Cash & Short-Term Investments | 8.39M | 3.64M | 7.81M | 8M | 3.78M | 1.19M | 7.85M | 5.96M | 2.45M | 26.79M |
| Cash Only | 8.39M | 3.64M | 7.81M | 8M | 3.78M | 1.19M | 7.85M | 5.96M | 2.45M | 3.79M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23M |
| Accounts Receivable | 932.59K | 53.83K | 23.68K | 18.44K | 4.86K | 90.97K | 529.56K | 1.37M | 2.05M | 601.2K |
| Days Sales Outstanding | - | 29.36 | 21.21 | 4.07 | 0.66 | 2.75K | - | - | - | 13.71 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 629.59K | 455.76K | 83.93K | 0 | 0 | 343.07K | 233.38K | 270.25K |
| Total Non-Current Assets | 58.59K | 5.58M | 5.85M | 5.8M | 5.79M | 13.58M | 11.14M | 11M | 8.97M | 6.78M |
| Property, Plant & Equipment | 0 | 38.04K | 55.75K | 43.52K | 16.85K | 114.49K | 283.41K | 172.17K | 114.95K | 62.4K |
| Fixed Asset Turnover | - | 17.59x | 7.31x | 37.97x | 159.44x | 0.11x | - | - | - | 256.40x |
| Goodwill | 0 | 5.44M | 0 | 1.53M | 1.53M | 3.63M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 5.44M | 4.16M | 4.13M | 9.73M | 10.77M | 10.74M | 8.81M | 0 |
| Long-Term Investments | 0 | 103.82K | 45K | 45K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 58.59K | 100.31K | 352.13K | 76.71K | 114.4K | 102.07K | 87.96K | 82.26K | 45.03K | 6.72M |
| Total Assets | 9.51M | 9.73M | 14.31M | 14.28M | 10.11M | 15.3M | 20.13M | 18.68M | 13.71M | 36.48M |
| Asset Turnover | - | 0.07x | 0.03x | 0.12x | 0.27x | 0.00x | - | - | - | 0.44x |
| Asset Growth % | 5.76% | 0.02% | 0.47% | -0% | -0.29% | 0.51% | 0.32% | -0.07% | -0.27% | 1.66% |
| Total Current Liabilities | 3.42M | 7.31M | 14.83M | 3.86M | 1.41M | 1.98M | 1.61M | 3.27M | 1.63M | 6.01M |
| Accounts Payable | 417.7K | 1.41M | 706.09K | 63.65K | 210.29K | 434.76K | 160.62K | 1.01M | 206.26K | 415.59K |
| Days Payables Outstanding | 121.29K | 61.2 | 24.95 | 2.88 | 15.7K | 48.49 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 212.28K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 652.61K | 989.48K | 1.01M | 387.83K | 0 | 0 | 0 | 322.38K | 0 | 3.31M |
| Current Ratio | 2.76x | 0.57x | 0.57x | 2.19x | 3.06x | 0.87x | 5.59x | 2.35x | 2.90x | 4.94x |
| Quick Ratio | 2.76x | 0.57x | 0.57x | 2.19x | 3.06x | 0.87x | 5.59x | 2.35x | 2.90x | 4.94x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 2.75M | 1.4M | 1.48M | 2.08M | 3.59M | 3.94M | 4M | 5.97M | 4.72M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 278.19K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 16.07K | 4.86K | 0 | 0 | 35.63K | 90.57K | 0 | 59.82K | 33.81K |
| Deferred Tax Liabilities | 0 | 1.53M | 183.92K | 269.97K | 365.36K | 728.93K | 802.13K | 689.12K | 779.44K | 0 |
| Other Non-Current Liabilities | 0 | 1.21M | 1.21M | 1.21M | 1.71M | 2.55M | 3.05M | 3.31M | 5.13M | 4.68M |
| Total Liabilities | 3.42M | 10.06M | 16.23M | 5.34M | 3.49M | 5.57M | 5.55M | 7.27M | 7.6M | 10.72M |
| Total Debt | 0 | 28.71K | 16.07K | 4.71K | 83.93K | 574.4K | 209.41K | 105.78K | 106.89K | 57.17K |
| Net Debt | -8.39M | -3.61M | -7.79M | -8M | -3.69M | -611.28K | -7.65M | -5.86M | -2.35M | -3.74M |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.06x | 0.01x | 0.01x | 0.02x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.82x |
| Interest Coverage | -3.45x | -48533.99x | -11982.91x | -10427.60x | -21541.46x | -1640.91x | -2077.91x | -1431.51x | -1130.69x | 210.31x |
| Total Equity | 6.09M | -329.42K | -1.93M | 8.94M | 6.62M | 9.73M | 14.58M | 11.41M | 6.11M | 25.76M |
| Equity Growth % | 1.15% | -1.05% | -4.85% | 5.64% | -0.26% | 0.47% | 0.5% | -0.22% | -0.46% | 3.22% |
| Book Value per Share | 592.50 | -22.37 | -81.08 | 151.11 | 83.28 | 84.76 | 60.47 | 15.58 | 11.36 | 6.24 |
| Total Shareholders' Equity | 6.09M | -329.42K | -1.93M | 8.94M | 6.62M | 9.73M | 14.58M | 11.41M | 6.11M | 25.76M |
| Common Stock | 76.57K | 101.31K | 172.57K | 437.94K | 40.78K | 55.56K | 3.17K | 17.99K | 77.08K | 267.68K |
| Retained Earnings | -65.26M | -78.6M | -91.82M | -93.15M | -100.25M | -107.11M | -120.88M | -134.46M | -146.98M | -143.38M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 114.79K | 120.19K | 127.47K | 134.33K | 139.47K | -802 | -86.43K | -182.74K | -182.8K | -282.16K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.46M | -8.41M | -6.47M | -10.84M | -8.15M | -7.32M | -10.68M | -10.43M | -9.56M | 8.56M |
| Operating CF Margin % | - | -12.57% | -15.87% | -6.56% | -3.04% | -606.78% | - | - | - | 0.53% |
| Operating CF Growth % | -3.69% | -0.89% | 0.23% | -0.68% | 0.25% | 0.1% | -0.46% | 0.02% | 0.08% | 1.9% |
| Net Income | -8.39M | -13.34M | -13.22M | -10.81M | -7.1M | -6.86M | -13.77M | -13.58M | -12.51M | 3.59M |
| Depreciation & Amortization | 1.26K | 5.18K | 19.29K | 38.48K | 213.93K | 33.4K | 45.3K | 41.61K | 51.8K | 19.2K |
| Stock-Based Compensation | 1.22M | 511K | 870.31K | 875.29K | 852.23K | 723.86K | 842.48K | 462.45K | 754.94K | 656.59K |
| Deferred Taxes | 0 | -511K | -1.34M | 86.05K | 0 | 12.05K | -192.6K | -113.01K | 90.32K | -288.75K |
| Other Non-Cash Items | 1.68M | 511K | 91.05K | 2.28M | -1.93M | -903.5K | 3.44M | 2.1M | 3.88M | 911.27K |
| Working Capital Changes | 1.02M | 4.41M | 7.11M | -1.03M | -192.54K | -321.21K | -1.04M | 668.51K | -1.82M | 3.67M |
| Change in Receivables | -907.5K | 3.24M | 32.44K | -685.74K | 0 | -18.96K | -441.2K | -872.74K | -548.11K | 1.03M |
| Change in Inventory | 167.44K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -148.25K | 712.79K | -706.04K | -642.43K | 0 | 136.7K | -310.67K | 782.46K | -808.02K | 226.12K |
| Cash from Investing | -20K | 149.75K | -37K | -270K | 0 | -244.44K | -157.02K | 6.38K | 0 | -22.66M |
| Capital Expenditures | 0 | -11K | -37K | -270K | 0 | -20.08K | -63.87K | 0 | 0 | -6.26K |
| CapEx % of Revenue | - | 0.02% | 0.09% | 0.16% | - | 1.66% | - | - | - | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -20K | -25K | 0 | -250 | 0 | 0 | 0 | 6.38K | 0 | 0 |
| Cash from Financing | 12.62M | 3.5M | 10.67M | 11.3M | 3.92M | 5M | 17.58M | 8.62M | 5.97M | 15.5M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -1.49M | -267.61K | 82.17K | 1.2M | 3.93M | -280.69K | 50K | 3.26M | -1M | 499.29K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -4.46M | -8.42M | -6.51M | -11.11M | -8.15M | -7.34M | -10.74M | -10.43M | -9.56M | 8.55M |
| FCF Margin % | - | -12.59% | -15.96% | -6.73% | -3.04% | -608.45% | - | - | - | 0.53% |
| FCF Growth % | -3.69% | -0.89% | 0.23% | -0.71% | 0.27% | 0.1% | -0.46% | 0.03% | 0.08% | 1.89% |
| FCF per Share | -434.07 | -572.18 | -273.73 | -187.94 | -102.53 | -63.92 | -44.54 | -14.24 | -17.76 | 2.07 |
| FCF Conversion (FCF/Net Income) | 0.53x | 0.63x | 0.49x | 1.00x | 1.15x | 1.07x | 0.78x | 0.77x | 0.76x | 2.38x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -137.89% | -463.53% | - | -308.49% | -91.22% | -83.92% | -113.3% | -104.54% | -142.88% | 22.56% |
| Return on Invested Capital (ROIC) | - | - | - | -868.28% | -271.61% | -85.52% | -133.03% | -147.92% | -202.78% | 26.24% |
| Gross Margin | - | -1158.49% | -2434.94% | -387.48% | 99.82% | -27038.66% | - | - | - | 100% |
| Net Margin | - | -1993.76% | -3243.52% | -654.24% | -264.21% | -56901.65% | - | - | - | 22.47% |
| Debt / Equity | - | - | - | 0.00x | 0.01x | 0.06x | 0.01x | 0.01x | 0.02x | 0.00x |
| Interest Coverage | -3.45x | -48533.99x | -11982.91x | -10427.60x | -21541.46x | -1640.91x | -2077.91x | -1431.51x | -1130.69x | 210.31x |
| FCF Conversion | 0.53x | 0.63x | 0.49x | 1.00x | 1.15x | 1.07x | 0.78x | 0.77x | 0.76x | 2.38x |
| Revenue Growth | - | - | -39.11% | 305.51% | 62.54% | -99.55% | -100% | - | - | - |
Kiora Pharmaceuticals, Inc. (KPRX) has a price-to-earnings (P/E) ratio of 2.5x. This may indicate the stock is undervalued or faces growth challenges.
Kiora Pharmaceuticals, Inc. (KPRX) reported $16.0M in revenue for fiscal year 2024.
Kiora Pharmaceuticals, Inc. (KPRX) grew revenue by 0.0% over the past year. Growth has been modest.
Kiora Pharmaceuticals, Inc. (KPRX) reported a net loss of $8.5M for fiscal year 2024.
Kiora Pharmaceuticals, Inc. (KPRX) has a return on equity (ROE) of 22.6%. This is excellent, indicating efficient use of shareholder capital.
Kiora Pharmaceuticals, Inc. (KPRX) had negative free cash flow of $10.0M in fiscal year 2024, likely due to heavy capital investments.